Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Ein externer Link zum Volltext ist derzeit nicht verfügbar.
Application of recombinant human erythropoietin in endovascular graft exclusion for thoracic aortic dissection
0
Zitationen
1
Autoren
2002
Jahr
Abstract
Objective:To evaluate the clinical significance and safety of recombinant human erythropoietin (rhEPO) in endovascular graft exclusion(EVGE) for thoracic aortic dissection(TAD). Methods: Twenty patients underwent EVGE for Stanford B type of TAD were randomly divided into 2 groups in a prospective controlled study. The experimental group(10 patients) received rhEPO(1×10 4 U/d×10 d,sc),while the control group was treated whithout rhEPO. The change of hemoglobin(Hb),hematocrit(HCT),platelet(Plt) count and blood pressure were measured prior to operation,and 1,3,7,14 d postoperation. Results: There were significant difference between 2 groups in Hb and HCT, and no significant difference in Plt count and blood pressure. No side effect was found. Conclusion: It is effective and safe to use rhEPO to relieve blood loss and anemia before EVGE.
Ähnliche Arbeiten
The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
1996 · 22.222 Zit.
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
2017 · 4.816 Zit.
Anemia of Chronic Disease
2005 · 3.718 Zit.
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 · 2.738 Zit.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 · 2.180 Zit.